EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluating prediction of short‐term tolerability of five type 2 diabetes drug classes using routine clinical features: UK population‐based study

Pedro Cardoso iD, Katie G Young iD, Rhian Hopkins iD, Bilal A Mateen iD, Ewan R Pearson iD, Andrew T Hattersley iD, Trevelyan J McKinley iD, Beverley M Shields iD, John M Dennis iD, MASTERMIND consortium

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16470 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Pedro Cardoso und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR Exeter Clinical Research Facility, Wellcome Trust, National Institute for Health and Care Research Exeter Biomedical Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

A precision medicine approach in type 2 diabetes (T2D) needs to consider potential treatment risks alongside established benefits for glycaemic and cardiometabolic outcomes. Considering five major T2D drug classes, we aimed to describe variation in short‐term discontinuation (a proxy of overall tolerability) by drug and patient routine clinical features and determine whether combining features in a model to predict drug class‐specific tolerability has clinical utility. Materials and Methods UK routine clinical data (Clinical Practice Research Datalink, 2014–2020) of people with T2D initiating glucagon‐like peptide‐1 receptor agonists (GLP‐1RA), dipeptidyl peptidase‐4 inhibitors (DPP4i), sodium‐glucose co‐transporter‐2 inhibitors (SGLT2i), thiazolidinediones (TZD) and sulfonylureas (SU) in primary care were studied. We first described the proportions of short‐term (3‐month) discontinuation by drug class across subgroups stratified by routine clinical features. We then assessed the performance of combining features to predict discontinuation by drug class using a flexible machine learning algorithm (a Bayesian Additive Regression Tree).

Results

Amongst 182 194 treatment initiations, discontinuation varied modestly by clinical features. Higher discontinuation on SGLT2i and GLP‐1RA was seen for older patients and those with longer diabetes duration. For most other features, discontinuation differences were similar by drug class, with higher discontinuation for patients who had previously discontinued metformin, females and people of South‐Asian and Black ethnicities. Lower discontinuation was seen for patients currently taking statins and blood pressure medication. The model combining all sociodemographic and clinical features had a low ability to predict discontinuation (AUC = 0.61).

Conclusions

A model‐based approach to predict drug‐specific discontinuation for individual patients with T2D has low clinical utility. Instead of likely tolerability, prescribing decisions in T2D should focus on drug‐specific side‐effect risks and differences in the glycaemic and cardiometabolic benefits of available medication classes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsHumansFemaleMaleUnited KingdomMiddle AgedAgedSulfonylurea CompoundsDipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsPrecision MedicineAdult

Stichwörter der Autor:innen

DPP4iGLP‐1RASGLT2iSUTZDanti‐hyperglycaemic treatmentclinical caredrug tolerabilityprecision medicinetreatment effect heterogeneity

Substanzen

Hypoglycemic AgentsSulfonylurea CompoundsDipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, UK.
  • Institute of Health Informatics, University College London, London, UK.
  • Division of Molecular & Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.

ORCID-Profile: Pedro Cardoso, Katie G Young, Rhian Hopkins, Bilal A Mateen, Ewan R Pearson, Andrew T Hattersley, Trevelyan J McKinley, Beverley M Shields, John M Dennis

Förderung

  • NIHR Exeter Clinical Research Facility
  • Wellcome Trust
  • National Institute for Health and Care Research Exeter Biomedical Research Centre
  • Wellcome Trust Early Career award
  • Medical Research Council

Zitieren

APA

Cardoso, P., Young, K. G., Hopkins, R., Mateen, B. A., Pearson, E. R., Hattersley, A. T., McKinley, T. J., Shields, B. M., Dennis, J. M., & MASTERMIND consortium (2025). Evaluating prediction of short‐term tolerability of five type 2 diabetes drug classes using routine clinical features: UK population‐based study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16470

Vancouver

Cardoso P, Young KG, Hopkins R, Mateen BA, Pearson ER, Hattersley AT, et al. Evaluating prediction of short‐term tolerability of five type 2 diabetes drug classes using routine clinical features: UK population‐based study. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16470

BibTeX
@article{Cardoso2025,
  author = {Cardoso, Pedro and Young, Katie G and Hopkins, Rhian and Mateen, Bilal A and Pearson, Ewan R and Hattersley, Andrew T and McKinley, Trevelyan J and Shields, Beverley M and Dennis, John M and MASTERMIND consortium, MASTERMIND consortium},
  title = {Evaluating prediction of short‐term tolerability of five type 2 diabetes drug classes using routine clinical features: UK population‐based study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16470}
}
Kostenlos starten →